Greg Finak News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Startup of the Year: Vote for the hottest up-and-coming company at the GeekWire Awards April 19, 2021 at 10:32 pm Coverage of the 2021 GeekWire Awards, presented by Wave Business, the Pacific NW’s annual startup and technology awards. See all coverage. The five finalists for this year’s Startup of the Year category at the GeekWire Awards reflect the strength of the entrepreneurial ecosystem in Seattle and the greater Pacific Northwest. Common Room; Ozette; SeekOut; Shelf Engine; and Strike Graph are on the brink of stardom. But more importantly, they are innovating, executing, and making ...

MedCity News Startup Ozette unveils AI approach to understanding the immune system Ozette applies artificial intelligence to immune monitoring to gain greater insight into a cancer patient's immune system. Beyond informing treatment decisions, the technology can guide drug and diagnostic development. Shares1   Cancer patients receive a check-in to see how their immune cells are working and whether the disease is responding to treatment. This immune monitoring is a routine part of cancer care and it helps guide treatment decisions. Yet current analysis methods remain limited, according to A...

Phase 1 clinical trial of novel HIV vaccine approach shows promising results A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine. This study demonstrates proof of principle for a new vaccine concept for HIV, a concept that could be applied to other path...

Phase 1 Clinical Trial Confirms HIV Vaccine Approach by Angela Mohan on  February 4, 2021 at 11:12 AM Phase 1 clinical trial testing a novel vaccine against HIV has produced promising results, IAVI and Scripps Research announced. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine. "This study demonstrates proof of principle for a new vaccine concept for HIV, a concept that could...

Loading video... VIDEO: A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced. The vaccine showed success in stimulating production of... view more  Credit: Scripps Research NEW YORK and LA JOLLA, CA--A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating vir...